PARP Inhibitor in Platinum-Resistant Ovarian Cancer: Single-Center Real-World Experience

PURPOSEPoly (ADP-ribose) polymerase inhibitors (PARPi) have proven efficacy in treatment of BReast CAncer (BRCA) gene mutation-positive platinum-sensitive ovarian cancers. There is paucity of data for their role in platinum-resistant ovarian cancer (PROC). We report here retrospective analysis of ou...

Descripció completa

Dades bibliogràfiques

Autors principals:	Amit Agarwal, Saphalta Baghmar, Chandragouda Dodagoudar, Suhail Qureshi, Aseem Khurana, Vikas Vaibhav, Guresh Kumar
Format:	Artigo
Idioma:	Inglês
Publicat:	American Society of Clinical Oncology 2021-12-01
Col·lecció:	JCO Global Oncology
Accés en línia:	https://ascopubs.org/doi/10.1200/GO.20.00269
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!